Clinical trials: Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and…
- Trial name
- NRR (NCT00454324)
- Testing
- Carboplatin, Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumor, Extensive-stage Small Cell Lung Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.
- Trial name
- NCT04101357
- Testing
- BNT411, Atezolizumab, Carboplatin
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 54 people
- Sponsor
- BioNTech SE
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Extensive Stage Small Cell Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00057837
- Testing
- G-CSF, Cisplatin, Etoposide
- Where
- 79 sites in United States
- Volunteers
- 140 people
- Sponsor
- Eastern Cooperative Oncology Group
Small Cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and…
- Trial name
- NCT03041311
- Testing
- Trilaciclib, Carboplatin, Etoposide
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
- Trial name
- MERU (NCT03033511)
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 308 sites in United States, Australia and 39 more
- Volunteers
- 748 people
- Sponsor
- AbbVie
Small-cell Lung Cancer, Brain Metastases
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
This is a single arm, multicenter phase II trial for 60 patients with untreated extensive stage (ES) small cell lung cancer (SCLC) with asymptomatic brain metastases.
- Trial name
- NCT04610684
- Testing
- Carboplatin, Etoposide, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Jeffrey Clarke
Extensive Stage Small Cell Lung Cancer
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1…
- Trial name
- DeLLphi-307 (NCT06502977)
- Testing
- Tarlatamab
- Where
- 12 sites in China
- Volunteers
- 32 people
- Sponsor
- Amgen
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Extensive-Stage Small Cell Lung Cancer
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous…
- Trial name
- NCT00616109
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.
- Trial name
- NCT04422210
- Testing
- Venetoclax, Atezolizumab, Carboplatin
- Where
- 5 sites in United States, Denmark and 2 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01840579
- Testing
- Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 200 mg
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive Stage Lung Small Cell Carcinoma
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
This phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
- Trial name
- NCT02899728
- Testing
- Carboplatin, Cediranib, Cediranib Maleate
- Where
- 24 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase II clinical trial studies whether the addition of nivolumab to cisplatin (or carboplatin) and etoposide will improve outcomes when treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT03382561
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 779 sites in United States
- Volunteers
- 160 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Small Cell, Lung Cancer
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer.
- Trial name
- NCT00284154
- Testing
- Vinflunine
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Carcinoma, Small Cell
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC.
- Trial name
- NCT00305942
- Testing
- Topotecan, carboplatin
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
In this study, all patients must have already completed first-line chemotherapy to treat extensive-stage disease small cell lung cancer.
- Trial name
- CheckMate 451 (NCT02538666)
- Testing
- Nivolumab, Ipilimumab
- Where
- 197 sites in United States, Argentina and 30 more
- Volunteers
- 907 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00726986
- Testing
- cisplatin, etoposide, sorafenib tosylate
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Afshin Dowlati, MD
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This randomized phase II trial is studying topotecan to see how well it works when given with or without aflibercept in treating patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00828139
- Testing
- ziv-aflibercept, topotecan hydrochloride
- Where
- 257 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)